A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)

NCT07684599 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

610

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms, Endometrial

Interventions

DRUG: Mocertatug rezetecan
DRUG: Dostarlimab
DRUG: Pembrolizumab

Sponsor

GlaxoSmithKline

Collaborators

[object Object]